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Abstract Interventions to reduce the cardiotoxicity of
doxorubicin are clinically relevant. Pharmacological pre-
conditioning mimicking ischemic preconditioning has been
demonstrated with morphine and represents an acceptable
clinical intervention. The purpose of this study was to
examine if pretreatment in vivo with morphine could
reduce doxorubicin-induced cardiotoxicity ex vivo in a rat
model. Wistar rats were divided into six groups and pre-
treated with an intraperitoneal (i.p.) injection of 3 or
10 mg/kg morphine, 1 mg/kg naloxone and saline, 1 mg/
kg naloxone and 3 mg/kg morphine or saline, 60 min
before excision of the heart. Biochemical indices such as
troponin T (TnT) and hydrogen peroxide (H2O2) in effluate
were measured together with physiological parameters in
Langendorff hearts before and after doxorubicin infusion
(2 mg/mL 0.05 mL/min for 45 min). Myocardial content
of doxorubicin was measured at the end of infusion. Pre-
treatment with morphine, irrespective of dosage, produced
a significant loss in left ventricular-developed pressure and
an increase of TnT and H2O2 in effluate before doxorubicin
infusion (p \ 0.05). Morphine also produced a significant
increase in left ventricular end-diastolic pressure and an
increase of TnT and H2O2 in effluate (p \ 0.05) at the end
of doxorubicin infusion. Naloxone, a non-selective opioid
receptor antagonist, abolished the effects of morphine both
before and after doxorubicin infusion. Morphine, irre-
spective of dosage, increased myocardial content of
doxorubicin compared to pretreatment with saline
(p \ 0.05). Pretreatment with morphine is associated with
a cardiodepressive effect and enhances cardiotoxicity of
doxorubicin measured by increased myocardial accumula-
tion of doxorubicin and physiological and biochemical
indices. The negative effects observed in our rat model are
abolished by naloxone.
Keywords Doxorubicin  High-sensitivity cardiac
troponin T  Hydrogen peroxide  Heart  Doxorubicinol 
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Introduction
The anthracycline doxorubicin is a frequently prescribed
anticancer drug because of its effect on solid tumors as well
as haematological malignancies. However, its pronounced
cardiotoxicity limits long-term use and prevents effective
anticancer therapy [1]. Dose reduction protocols to avoid
the risk of delayed cardiotoxicity might be at the expense
of the anticancer effect [2]. Generation of reactive oxygen
species (ROS) and impaired calcium handling have been
proposed as toxic mechanisms to explain both acute and
delayed cardiotoxicity of anthracyclines [3–5].
Measurement of cardio-specific biomarkers can be a
valid diagnostic tool for early identification, assessment
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and monitoring of cardiotoxicity [6]. Cardiac troponins
have been suggested as valuable biomarkers of anthracy-
cline cardiotoxicity, both in animal and clinical studies [7,
8], and they are advantageous because samples are
obtained by a minimally invasive procedure and easily
analyzed. However, few reported studies have character-
ized the cardiac troponin response in chemically induced
chronic progressive myocardial injury such as we see with
doxorubicin exposure [9]. The sensitivity and precision of
the troponin T (TnT) assays have been improved in recent
years and clinically approved high-sensitivity assays now
detect cardiac troponins in nanogram per liter
concentration.
Morphine is a non-selective opioid receptor agonist.
Direct stimulation of myocardial d1-opioid receptors leads
to activation of mitochondrial KATP-channels and a resul-
tant increase in intracellular ROS in vitro. This is an
important component of the signaling pathways by which
morphine mimics preconditioning in cardiomyocytes [10].
Pharmacological preconditioning with morphine could
represent an acceptable clinical intervention to reduce the
cardiotoxicity of doxorubicin. Thus, it is of interest to study
how morphine interacts with the toxic mechanisms of
anthracyclines by measuring generation of ROS. To our
knowledge, only one study has previously investigated the
cardiac effect of intraperitoneal (i.p.) morphine before
doxorubicin i.p. in rats, and this study found that morphine
protects against doxorubicin cardiotoxicity [11]. A previ-
ous pilot study of 2-week duration, where we pretreated
rats in vivo with i.p. morphine or saline 60 min before i.p.
doxorubicin, every other day for 11 days, found that
morphine, on the contrary, increased mortality in combi-
nation with doxorubicin [28].
In order to explore our negative findings in the pilot study,
we pretreated rats in vivo with morphine before the hearts
were isolated and exposed to doxorubicin ex vivo in a
Langendorff model. Naloxone, a non-selective opioid
receptor antagonist, was administered to investigate whether
the potential effect of morphine would be abolished, or if
naloxone itself had an effect. The aim of this study was to
investigate the interaction of morphine and doxorubicin
exclusively in the heart. Measurement of relevant biochemi-
cal indices such as TnT and hydrogen peroxide (H2O2) in
effluate combined with physiological parameters and myo-
cardial content of doxorubicin were included in the model.
Materials and Methods
Materials
Doxorubicin was purchased from Meda AS (Slemmestad,
Norway), morphine, naloxone and pentobarbital from
Haukeland Hospital Pharmacy (Bergen, Norway), heparin
from Leo Pharma A/S (Oslo, Norway), and ingredients for
the Krebs-Henseleit bicarbonate buffer from Merck KGaA
(Darmstadt, Germany). This study conforms to the guide
for the care and use of laboratory animals published by the
US National Institutes of Health (NIH publication no.
85-23, revised 1996) and was approved by the Animal Care
and User Committee in Norway.
Animals
Male Wistar rats weighing 200 ± 20 g were purchased
from Taconic (Ejby, Denmark). The animals were housed
in grid-bottom metal wire cages in a room maintained at a
12 h light–dark cycle at a temperature of 20–22 C. They
were acclimatized for 2 weeks, housed four per cage and
allowed free access to food pellets (Pellets rodent, Special
Diets Services, Essex, UK) and tap water until injection of
morphine, naloxone, saline or doxorubicin. The animals
were separated in individual cages based on their respec-
tive treatment protocols.
Langendorff Perfusion Model
The perfusion medium was a modified, oxygenated (95 %
O2 and 5 % CO2) Krebs-Henseleit bicarbonate buffer
(KHBB) (pH 7.4) containing in mM: 118.5 NaCl, 25.0
NaHCO3, 1.2 MgSO4, 4.7 KCl, 1.2 KH2PO4, 11.0 D-glu-
cose, and 1.25 CaCl2. Hearts were excised after anesthesia
of the rats with an i.p. injection of pentobarbital 50 mg/kg
(0.1 mL/100 g bodyweight) and heparinized i.p. (0.1 mL
500 IU/100 g bodyweight). Anesthesia was evaluated by
the pedal-withdrawal reflex. The heart was rapidly excised
and immediately placed in cold (4 C) KHBB to tempo-
rarily stop its beating and preserve it from ischemic injury
prior to perfusion. The heart was mounted on a steel can-
nula placed in the aorta and perfused retrogradely in a
Langendorff system with the use of thermostated (37 C)
reservoirs (Lauda, Lauda-Ko¨nigshofen, Germany), perfu-
sion lines and heart chamber. Volume-regulated flow
(12.5 mL/min) was performed by use of an Alitea peri-
staltic pump (Alitea, Stockholm, Sweden). A perfusion
pump (B. Braun, Melsungen, Germany) connected to a side
arm of the aortic cannula was used for administration of
doxorubicin or KHBB ex vivo. A water-filled latex balloon
was placed in the left ventricle and connected to a pressure
transducer (Memscap AS, Skoppum, Norway) for the
recording of left ventricular pressure (LVDP) and sec-
ondarily derived contractility indices. Left ventricular end-
diastolic pressure (LVEDP) was adjusted between 4 and
8 mmHg. A second pressure transducer was connected to a
side arm on the aortic cannula for the recording of aortic
pressure (AoP), as an index of coronary vascular resistance
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during volume-regulated perfusion. Pressure signals were
amplified (Quadbridge, AD Instruments, London, UK) and
recorded using a PowerLab data acquisition system (AD
Instruments, East Sussex, UK). AoP, LVDP, LVEDP, left
ventricular pressure first derivatives maximum (dp/dtmax)
and minimum (dp/dtmin) were displayed and recorded.
Pacing (300 beats per minute by electric stimulation of 5 V
amplitude of 3 ms duration) during the doxorubicin or
KHBB ex vivo protocol was obtained by placing one
electrode on the right auricle and one on the steel cannula.
Pacing was used to maintain a standard contractile
response to the experimental drugs in the model not
influenced by changes in heart rate and/or periods of
arrhythmia. Effluate of KHBB mixed with doxorubicin was
sampled for measurements of doxorubicin concentration in
the perfusion system before mounting of the hearts. Ef-
fluate samples of 1 mL were collected in 1.5 mL poly-
propylene Eppendorf micro-test tubes (Eppendorf Vertrieb,
Wesseling-Berzdorf, Germany) from each heart, at base-
line and at the end of the perfusion protocol, and stored at
08 C, until analysis for TnT within 4 days of termination of
the Langendorff protocol. Effluate samples of 1 mL were
collected in Eppendorf tubes from each heart, at baseline
and at the end of the perfusion protocol, and immediately
analyzed for H2O2. Samples were placed in a thermostated
(37 C) Eppendorf rack heated by a Lauda reservoir
(Lauda, Ko¨nigshofen, Germany). At the end of the perfu-
sion protocol, hearts were removed from the Langendorff
system, and myocardial tissue from the left ventricle was
dissected free and immediately frozen in liquid helium and
stored at -80 C until analysis of doxorubicin and doxo-
rubicinol within 14 days of termination of the Langendorff
protocol. All experiments and analysis were carried out
between 7 a.m. and 7 p.m.
Experimental Design
Rats were randomly divided into three morphine treatment
groups (3 or 10 mg/kg morphine or 3 mg/kg morphine and
1 mg/kg naloxone) and one naloxone group (1 mg/kg).
Naloxone was administrated 10 min before morphine or
saline. Two control groups were included: One pretreated
with 0.9 % saline before doxorubicin infusion, a control for
pretreatment, and one pretreated with 0.9 % saline before
KHBB infusion, a control for the experimental model. All
pretreatment was administrated by i.p. injection. Each
group included six rats. 60 min after pretreatment, hearts
were excised and Langendorff perfused with the following
protocol: 15-min stabilization period, after which physio-
logical parameters were recorded for 5 min and effluate
was collected. Hearts then received 45 min of infusion with
undiluted 2 mg/mL doxorubicin at a rate of 0.05 mL/min
(or KHBB for the control group). Physiological data were
collected immediately after the infusion was terminated.
Ultimately, a 5-min wash-out period followed after which
we collected effluates, and the Langendorff protocol was
terminated. Treatment protocols and perfusion protocols
are illustrated in Fig. 1.
Quantification of Doxorubicin and Doxorubicinol
Doxorubicin and doxorubicinol were quantified by high-
performance liquid chromatography (HPLC-MS/MS)
(1200 series RRLC, Agilent Technologies, USA) coupled
with an Agilent 6410 triple quadrupole mass spectrometer
using positive electrospray ionization (Agilent Technolo-
gies, USA). Frozen left ventricular tissue was minced and
weighted out in a glass tube with a screw cap and
homogenized in physiological saline (2 mL/100 mg tissue)
with a tissue homogenizer (Ultra Turrax, Sigma Aldrich,
Germany). 1000 lL of sample was added to 100 lL of
daunorubicin as internal standard (IS) and 200 lL of buffer
(1M TRIZMA, pH 11.1) and mixed well before extraction
with 4 mL ethyl acetate/heptane (80/20 vol/vol). The
samples were mixed using a rotary blender for 15 min and
then centrifuged at 3500 rpm for 10 min at 10 C. The
organic phase was evaporated to dryness at 50 C under
nitrogen then dissolved in 100 lL of methanol followed by
100 lL of distilled water. The extract was mixed thor-
oughly and transferred to silanized vials before analysis.
25 lL of extract was injected and separated on a Zorbax
SB-Aq (2.1 9 50 mm, 1.8 lm particles, Agilent Technol-
ogies, USA) column using gradient elution with acetoni-
trile and 0.1 % formic acid in water. Quantification were
performed using multiple reaction monitoring mode at m/
z 546.1 ? 363.1 for doxorubicinol, m/z 544.1 ? 361.1 for
doxorubicin and m/z 528.1 ? 321.1 for daunorubicin (IS).
Effluate Content of H2O2
H2O2 in cardiac effluate was measured using an Apollo
4000 electrochemical detection system (World Precision
Instruments, Sarasota, FL, USA). The electrode was cali-
brated using nine serial dilutions of H2O2 in phosphate-
buffered saline with added aniline. The current recorded
from the effluate was then calculated as lM H2O2. Samples
were kept at 37 C during measurement. The electrode was
allowed 3 min of stabilization and 1 min of recording.
Effluate Content of TnT
TnT in cardiac effluate was measured using an Elecsys
2010 immunoassay analyzer (Roche Diagnostics Norway
AS, Oslo, Norway), based on the sandwich principle. Total
duration of assay: 9 min. First incubation: 50 lL of sample,
a biotinylated monoclonal cardiac TnT-specific antibody,
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and a monoclonal cardiac TnT-specific antibody labeled
with a ruthenium complex (tris(2,2-bipyridyl)ruthe-
nium(II)-complex(Ru(bpy))) reacted to form a sandwich
complex. Second incubation: After addition of streptavi-
din-coated microparticles, the complex became bound to
the solid phase via interaction of biotin and streptavidin.
The reaction mixture was aspirated into the measuring cell
where the microparticles were magnetically captured onto
the surface of the electrode. Unbound substances were then
removed with ProCell. Application of a voltage to the
electrode then induced chemiluminescent emission which
was measured by a photomultiplier. Results were deter-
mined via a calibration curve which was instrument spe-
cifically generated by 2-point calibration and a master
curve (5-point calibration) provided via the reagent bar-
code. Detection limit was 5.0 ng/L.
Statistics
All results are reported as mean values ± standard devia-
tion (SD) in tables. Data were collected at two time points:
before doxorubicin infusion and at the end of infusion.
Groups were compared with regards to parameters with a
one-way analysis of variance and subsequently fisher’s
protected least-significant difference test. SPSS for
windows version 17.0 was used, and p \ 0.05 was con-
sidered statistically significant.
Results
All physiological results are presented in Table 1 and
pharmacological and biochemical results in Table 2.
Results from comparison of the two morphine groups have
been left out of Tables 1 and 2 as they showed no statis-
tically significant difference between the two different
morphine doses.
Reduction in cardiac function measured by LVDP and
release of troponin and H2O2 were evident in hearts from
morphine-treated rats before infusion with doxorubicin was
started. Hearts from rats pretreated with 3 mg/kg
(84.3 ± 8.3 mmHg) and 10 mg/kg (76.8 ± 5.8 mmHg)
morphine demonstrated significantly (p \ 0.05) lower
values of LVDP at baseline, compared with hearts pre-
treated with saline (149.8 ± 10.7 mmHg). There was no
difference in LVDP at baseline in hearts from rats pre-
treated with naloxone, or naloxone and 3 mg/kg morphine
compared with hearts pretreated with saline.
The reduction in cardiac function measured by LVDP
and release of troponin and H2O2 were more pronounced in
3mg/kg morphine 
10mg/kg morphine 
Saline   
MO3    =   3mg/kg morphine     
MO10  =   10 mg/kg morphine     
DOX    =   doxorubicin   
NAL    =    naloxone     
SAL     =    saline 
                                    = intraperitoneal injection 
E = excision of heart and end of in vivo protocol 
6 rats in each group
In vivo 
1mg/kg naloxone  
& saline    
Groups 
SAL               60’                 E        
MO10                                  E 
1mg/kg naloxone & 
3mg/kg morphine  
Saline & KHBB   
MO3             60’                 E      
   NAL   10’   SAL    60’       E 
 NAL   10’  MO3    60’      E 
SAL              60’                  E 
Recording
Ex vivo Langendorff perfusion 
15’ 
15’ 
15’ 
15’ 
15’ 
15’ 
Infusion 
6 hearts in each group 
45’ DOX 
45’ KHBB 
45’ DOX 
45’ DOX
45’ DOX 
45’ DOX 
(infusion)
Stabilisation  period 
Fig. 1 Treatment and perfusion
protocols
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hearts from morphine-treated rats after doxorubicin expo-
sure, compared with hearts from saline or naloxone-treated
rats. Hearts from rats pretreated with 3 mg/kg (52.8 ±
11.1 mmHg) and 10 mg/kg (50.7 ± 10.9 mmHg) mor-
phine demonstrated significantly (p \ 0.05) lower values
of LVDP at the end of the doxorubicin infusion, compared
with hearts pretreated with saline (102.5 ± 5.9 mmHg).
There was no difference in LVDP at the end of the doxo-
rubicin infusion in hearts from rats pretreated with nalox-
one, or naloxone and 3 mg/kg morphine, compared with
hearts pretreated with saline. However, reduction in phys-
iological parameters in per cent was similar in all groups
1–5, irrespective of pretreatment during 45 min of doxo-
rubicin infusion.
At the end of infusion, hearts from rats pretreated with 3 mg/
kg (23.2 ± 1.8 mmHg) and 10 mg/kg (22.4 ± 1.8 mmHg)
morphine demonstrated significantly (p\ 0.05) higher
LVEDP, compared with hearts pretreated with saline
(13.2 ± 1.7 mmHg). There was no significant difference in
LVEDP in the naloxone-pretreated groups, compared with the
saline-pretreated group, at the end of infusion.
Hearts from rats pretreated with 3 mg/kg (33.6 ± 0.5
lM) and 10 mg/kg (39.5 ± 5.8 lM) morphine demon-
strated significantly (p \ 0.05) increased release of H2O2
in effluate compared with hearts pretreated with saline
(28.4 ± 2.1 lM), at baseline. Similarly, H2O2 in effluate
from rats pretreated with 3 mg/kg (40.9 ± 3.6 lM) and
10 mg/kg (45.6 ± 1.3 lM) morphine was increased at the
end of infusion, compared with H2O2 in effluate from rats
pretreated with saline (34.9 ± 1.2 lM).
Hearts from rats pretreated with 3 mg/kg (63.3 ±
20.7 ng/L) and 10 mg/kg (84.8 ± 20.3 ng/L) morphine
Table 1 Physiological results
Group 1
3 mg/kg
morphine
Group 2
10 mg/kg
morphine
Group 3
Saline
Group 4
1 mg/kg naloxone
and saline
Group 5
1 mg/kg naloxone
and 3 mg/kg
morphine
Group 6
Saline control
LVDP
baseline
(mmHg)
84.3 ± 8.3* 76.8 ± 5.8* 149.8 ± 10.7 145.3 ± 7.7 139.8 ± 9.1 145.7 ± 9.6
LVDP end
(mmHg)
52.8 ± 11.1* 50.7 ± 10.9* 102.5 ± 5.9 99.8 ± 7.7 100.3 ± 11.1 135.5 ± 6.6*
LVDP (%) 62.9 ± 13.3 66.2 ± 14.7 68.8 ± 7.5 68.6 ± 2.6 71.9 ± 7.9 93.1 ± 2.4*
LVEDP
baseline
(mmHg)
5.6 ± 1.6 6.1 ± 1.3 6.2 ± 1.5 5.6 ± 1.4 6.5 ± 1.3 7.4 ± 1.0
LVEDP end
(mmHg)
23.2 ± 1.8* 22.4 ± 1.8* 13.2 ± 1.7 13.5 ± 1.8 12.9 ± 1.4 8.6 ± 0.6*
LVEDP (%) 440.7 ± 124.9* 381.2 ± 94.1* 219.2 ± 44.2 254.4 ± 70.7 206.1 ± 53.9 117.7 ± 14.5
AoP baseline
(mmHg)
92.5 ± 4.4* 89.5 ± 6.1* 103.3 ± 4.1 107.0 ± 3.1 104.2 ± 5.2 107.7 ± 2.7
AoP end
(mmHg)
150.3 ± 5.8* 151.5 ± 6.6* 164.0 ± 5.8 159.2 ± 7.0 160.0 ± 7.2 114.6 ± 4.6*
AoP (%) 162.9 ± 11.9 169.7 ± 10.1 158.8 ± 6.5 148.7 ± 2.9 154.1 ± 12.6 106.4 ± 2.9*
dp/dtmax
baseline
(mmHg)
2,855.3 ± 378.5* 2,733.5 ± 458.5* 4,677.7 ± 306.2 4,934.8 ± 205.7 4,710.2 ± 125.5 4,788.7 ± 291.4
dp/dtmax end
(mmHg)
1,551.0 ± 293.8* 1,542.3 ± 278.9* 2,873.8 ± 418.4 2,902.8 ± 423.8 2,779.5 ± 588.1 4,378.3 ± 449.5*
dp/dtmax (%) 54.7 ± 10.2 58.0 ± 15.2 61.8 ± 10.6 58.7 ± 7.4 58.9 ± 12.2 91.3 ± 4.6*
dp/dtmin
baseline
(mmHg)
-1,767.8 ± 125.9* -1,853.0 ± 164.8* -3,191.5 ± 279.3 -3,184.8 ± 308.9 -3,049.5 ± 263.5 -3,746.5 ± 220.2*
dp/dtmin end
(mmHg)
-1,170.7 ± 107.9* -1,326.2 ± 143.2* -2,148.5 ± 378.8 -2,186.8 ± 196.6 -1,970.5 ± 177.9 -3,587.8 ± 282.0*
dp/dtmin (%) 66.3 ± 5.4 71.9 ± 8.5 67.1 ± 8.5 69.5 ± 11.6 65.1 ± 9.0 95.8 ± 4.5*
Values presented as mean ± SD
* Significantly different from hearts in group 3, p \ 0.05
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demonstrated significantly (p \ 0.05) higher values of TnT
at baseline, compared with hearts pretreated with saline
(22.7 ± 7.4 ng/L). There was no difference in TnT at
baseline in hearts from rats pretreated with naloxone, or
naloxone and 3 mg/kg morphine compared with hearts
pretreated with saline. Similarly, hearts from rats pretreated
with 3 mg/kg (321.5 ± 108.5 ng/L) and 10 mg/kg
(473.5 ± 117.6 ng/L) morphine demonstrated significantly
(p \ 0.05) higher values of TnT at the end of the doxo-
rubicin infusion, compared with hearts pretreated with
saline (129.2 ± 6.6 ng/L). There was no difference in TnT
at the end of the doxorubicin infusion in hearts from rats
pretreated with naloxone, or naloxone and 3 mg/kg mor-
phine compared with hearts pretreated with saline.
Myocardial content of doxorubicin was significantly
(p \ 0.05) higher in the 3 mg/kg (205.6 ± 27.6 nmol/g)
and 10 mg/kg (213.7 ± 11.1 nmol/g) morphine group
compared with the saline-pretreated group (168.5 ±
9.5 nmol/g), at the end of infusion. The concentration of
doxorubicin in the perfusate was measured to a mean of
5.42 ± 1.98 lM based on samples (n = 30) from the aortic
cannula of the Langendorff system without hearts mounted.
Hearts were paced to 300 beats per minute; thus, data on
heart rate have been left out of Table 1.
Discussion and Conclusion
The main observation in the present results is that the
increased mortality associated with morphine could be
related to enhanced cardiotoxicity. In the pilot study [28],
we established an in vivo model with three groups: eight
rats were pretreated with an i.p. injection of 3 mg/kg
morphine, and 8 rats were pretreated with an i.p. injection
of 0.9 % saline, 60 min prior to a 3 mg/kg doxorubicin i.p.
injection every other day for 11 days, up to a cumulative
dose of 12 mg/kg doxorubicin. Five rats were pretreated
with an i.p. injection of 0.9 % saline 60 min prior to an i.p.
injection of 0.9 % saline every other day for 11 days. On
day 12, hearts from the three groups were planned to be
excised and Langendorff perfused for comparison of
physiological and biochemical indices of cardiotoxicity.
However, 6 out of 8 rats in the group pretreated with
morphine died before day 12 and did not complete the
treatment protocol. Mortality was evident in the group by
day 9 (n = 1) and by days 10 and 11 (n = 5). The
remaining two rats were moribund and euthanasia was
performed. Thus, physiological parameters from rats pre-
treated with morphine were not available for comparison
with the other groups, and myocardial tissue was discarded
due to risk of postmortem redistribution of drugs. Based on
these results, we hypothesized that the interaction between
doxorubicin and morphine could result in increased car-
diotoxicity. The results from the pilot study were unex-
pected because a similar study [11] found morphine to be
protective against doxorubicin-induced cardiotoxicity in
rat. This study pretreated rats with an i.p. dose of 10 mg/kg
morphine 30 min prior to doxorubicin. Doxorubicin
(1.25 mg/kg i.p.) was administrated four times per week
for 4 weeks, with a total cumulative dose of 20 mg/kg.
Table 2 Pharmacological and biochemical results
Group 1
3 mg/kg
morphine
Group 2
10 mg/kg
morphine
Group 3
Saline
Group 4
1 mg/kg
naloxone and
Saline
Group 5
1 mg/kg
naloxone and
3 mg/kg
morphine
Group 6
Saline
control
Doxorubicin myocardial tissue
concentration at the end of
experiments (nmol/g)
205.6 ± 27.6* 213.7 ± 11.1* 168.5 ± 9.5 185.2 ± 7.7 188.8 ± 11.7 0.0
Doxorubicinol myocardial tissue
concentration at the end of
experiments (nmol/g)
3.1 ± 0.2 4.0 ± 1.4 3.2 ± 0.5 1.4 ± 0.5* 2.1 ± 0.5* 0.0
Troponin T in effluate before
doxorubicin exposure (ng/L)
63.3 ± 20.7* 84.8 ± 20.3* 22.7 ± 7.4 39.0 ± 15.7 47.0 ± 4.6 16.8 ± 3.8
Troponin T in effluate after doxorubicin
exposure (ng/L)
321.5 ± 108.5* 473.5 ± 117.6* 129.2 ± 6.6 177.8 ± 4.6 187.2 ± 8.2 36.0 ± 10.0
H2O2 in effluate before doxorubicin
exposure (lM)
33.6 ± 0.5* 39.5 ± 5.8* 28.4 ± 2.1 26.9 ± 3.6 26.9 ± 3.6 27.6 ± 3.3
H2O2 in effluate after doxorubicin
exposure (lM)
40.9 ± 3.6* 45.6 ± 1.3* 34.9 ± 1.2 33.3 ± 1.8 33.9 ± 2.5 28.8 ± 3.4*
Values presented as mean ± SD
* Significantly different from hearts in group 3, p \ 0.0.5
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Cardioprotective efficacy of morphine was performed by
analyzing the electrocardiographic parameters (QRS com-
plexes and ST segments) and contractility force of left
ventricular papillary muscle, and these parameters were
improved in rats pretreated with morphine. Morphine also
reduced mortality in this study. We measured LVDP and
derived indices. The morphine dose is the same in our
study. However, we delivered it 60 min prior to doxoru-
bicin. In early preconditioning, a memory phase of up to
2 h after trigging has been reported in which protection is
demonstrated [12, 13]. Theoretically, this should allow for
opioid receptor activation in the memory phase of pre-
conditioning in the rat myocardium.
Enhanced mortality by a combination of morphine and
doxorubicin has previously been demonstrated in mice
where morphine pretreatment caused a dose-dependent
increase in plasma doxorubicin [14]. In our study, rats were
pretreated in vivo with morphine before the hearts were
isolated and exposed to doxorubicin ex vivo. Pretreatment
with morphine in vivo, irrespective of dose, is associated
with a cardiodepressive effect in isolated hearts combined
with increased release of H2O2 and TnT. After exposure to
doxorubicin ex vivo, isolated hearts from rats pretreated
with morphine, irrespective of dose, demonstrate increased
release of H2O2 and TnT, increased myocardial contracture
and increased myocardial accumulation of doxorubicin.
These effects were abolished when naloxone was admin-
istrated before morphine in pretreatment. The enhanced
cardiotoxicity of pretreatment with morphine was in par-
ticular evident by LVEDP. Myocardial contracture asses-
sed by an increase in LVEDP suggests that pretreatment
with morphine enhanced diastolic dysfunction during
doxorubicin infusion. Diastolic dysfunction is proposed to
reflect impaired calcium handling which together with
generation of oxygen species are proposed as toxic mech-
anisms of anthracyclines [3]. Interestingly, diastolic dys-
function is proposed to precede systolic dysfunction in
chronic anthracycline cardiotoxicity and suggested as an
early marker of subsequent heart failure in the clinic [3].
By using i.p. administration of 4 mg/kg morphine, a
study on rats found peak plasma concentrations of about 1
lM after 8 min with a half-life of about 46 min [15].
Theoretically, this should allow for opioid receptor acti-
vation in the memory phase of preconditioning in the rat
myocardium. In early preconditioning, a memory phase of
up to 2 h after trigging has been reported in which pro-
tection is demonstrated [12, 13]. We used a dose of 3 mg/
kg i.p and added a dosage of morphine of 10 mg/kg as
reported by others [11, 16, 17], to investigate whether the
dose used in the pilot study was too low to illicit a pro-
tective effect. However, both 3 and 10 mg/kg morphine i.p.
had a cardiodepressive effect prior to exposure to doxo-
rubicin. In this present study, cardiodepression with a
theoretical morphine peak plasma concentration of
approximately 1 lM is in accordance with previous
observations [18].
In vitro studies have shown that opioids directly
decrease the contractile response of isolated ventricular
cardiomyocytes to electrical stimulation [19]. One
hypothesis explaining morphine-induced decreased con-
tractility is that morphine induced the increase in genera-
tion of free radicals that we measured at baseline. A study
of pretreatment of chick embryonic ventricular myocytes
with 1 lM morphine before 1 h of ischemia and 3 h of
reoxygenation found a two-fold increased free radical
production before ischemia compared with controls [20].
The increase in free radical signals with morphine was
abolished by 5-hydroxydecanoate, a selective mitochon-
drial KATP-channel antagonist [10]. We observed that the
cardiodepressive effect was associated with increased
release of H2O2 in morphine-treated hearts. However, after
doxorubicin infusion, this was associated with further
increased release of hydrogen peroxide and increased
myocardial contracture evident by increased LVEDP. This
raises the question whether an increase in generation of
free radicals induced by morphine not only induced a
cardiodepressive effect prior to doxorubicin, but produced
additive myocardial damage to that produced by doxoru-
bicin. H2O2 is an important by-product of oxidative
metabolism and is a major contributor in oxidative stress-
induced functional and metabolic dysfunction [21, 22]. An
experiment that exposed isolated perfused rat hearts to
200 lM H2O2 for 30 min resulted in a time-dependent
depression of myocardial contractility and a 1000 % ele-
vation in LVEDP [4]. Similar results have been reported in
isolated rat hearts [23, 24]. We found a depression in
LVDP of approximately 40 % in the morphine groups and
30 % in the saline-pretreated group after 45 min of doxo-
rubicin exposure. This effect was associated with approx-
imately 400 % elevation in LVEDP in the morphine
groups, irrespective of dose, compared with 200 % in the
saline group with levels of H2O2 in the range of 35–45 lM.
Thus, our results suggest that additive free radical damage
generated by morphine and doxorubicin could result in
contractile dysfunction. H2O2 mediates increased endo-
thelial permeability and may increase the extravasation of
doxorubicin and alter its distribution in the myocardium
[25, 26]. Thus, a potential change in endothelial perme-
ability due to increased H2O2 can explain the increased
content of doxorubicin in hearts from rats pretreated with
morphine in our study.
The concentration of doxorubicin in the perfusate was
measured to 5.42 ± 1.98 lM. A non-physiological con-
centration could mask a protective effect of morphine.
However, Cmax of plasma doxorubicin following a 30 mg/
m2 i.v. bolus dose in humans is reported to be 3 lmol/L,
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with cellular levels 30–100-fold higher than that of the
plasma [27]. We do not know in which compartment of the
myocardium the accumulation of doxorubicin took place.
The main coronary vascular bed is unlikely due to our
wash-out procedure. Furthermore, the reduced contractile
function is not due to vasoconstrictive effects since we
used a model with volume-regulated perfusion. However,
doxorubicin could accumulate in the extracellular space as
well as in the cardiomyocytes. The reduced contractile
function suggests that at least a part of the accumulation
affects the cardiomyocytes. We observed that H2O2 levels
are altered by morphine in combination with doxorubicin.
However, there is insufficient assessment of why this might
lead to enhanced damage, and of the possibility that other
reactive species may also be involved in the effects seen.
Further studies are needed to assess this.
The Langendorff model bypasses the pharmacokinetic
phase associated with drug metabolism and only measures
the direct action of the drug in the myocardium. The
interaction of morphine and doxorubicin in vivo could
involve systemic effects that secondarily influenced the
function of the heart. In the present study, we wanted to
investigate how doxorubicin affects a heart that has already
been exposed to morphine in vivo based on our findings in
the pilot study where morphine was administrated in a
similar way. Ideally, heart functional parameters could be
measured in vivo after morphine and subsequent doxoru-
bicin administration, but direct cardiotoxic effects could be
difficult to separate from indirect systemic effects. Fur-
thermore, both morphine and doxorubicin could be
administrated in sequence in Langendorff hearts to study
their effects exclusively in the heart, but pharmacokinetic
effects would lack as mentioned above.
In conclusion, we found that pretreatment with mor-
phine is associated with a cardiodepressive effect in iso-
lated rat hearts combined with increased release of H2O2
and TnT. After exposure to doxorubicin ex vivo, isolated
hearts from rats pretreated with morphine are associated
with increased release of H2O2 and TnT, increased myo-
cardial contracture and accumulation of doxorubicin.
Morphine increases intracellular free radical signals, and
this is an important component of the signaling pathways
by which morphine mimics preconditioning in cardio-
myocytes. However, results in our pilot study and the
present study suggest that these pathways, although
promising interventions to reduce cardiotoxicity of anth-
racyclines, are also associated with risk of additional
damage in the rats.
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